Treatment with ZSTK-474 (a pan PI3K p110 inhibitor [28]), IPI-145 (Duvelisib@, a γ/δ PI3K p110 inhibitor [29]), GSK1120212 (Trametinib@, a MEK inhibitor [30]), or ABT199 (Venetoclax@, a Bcl2 inhibitor [31]) synergized with nelarabine in reducing cell survival in nelarabine-resistant T-ALL cells. Here, MAP2K7 is linked to acute lymphoblastic leukemia.